Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
about
Trial WatchElevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphomaPrognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma.Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control studyComprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphomaPersonalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaA phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma.Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma.Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.A non-invasive diagnosis of histiocytic necrotizing lymphadenitis by means of gene expression profile analysis of peripheral blood mononuclear cells.Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study.Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage.Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma
P2860
Q24618653-32A78A8B-719D-420D-973D-0EB62836D36EQ34626318-68291633-92D9-4614-B502-5FDDA47B0B17Q34882773-15233DD6-F2CD-48E2-9D6F-9D7CC59438BFQ35056309-D5C84547-1937-48E5-B213-452D034AEC59Q35186832-AD7739C4-AF0F-423E-A6AD-47AF3B888861Q36354265-6CF8CF6D-B464-4267-A156-32126F3E694EQ36384484-E3F17DA4-B2EF-41A4-B576-CDFD263DD1D5Q36710788-028937E1-12C6-47C3-BFBC-8F3046BDF117Q38259725-43F9A3DA-BDDF-4A67-BCDE-8D2D79B95693Q38376847-3268A584-E1D9-43E3-A09F-1CDA242A0BA7Q38850729-C10CBDF2-BD63-4786-9DE5-537EBB4CFDBAQ39037933-E5A0F94E-CB72-4B18-8C6D-D9962DDB3915Q40250329-C50D88A5-1ABD-4340-B7DF-31021E53F18CQ45398897-E8A7D507-37DF-4B98-8507-93BF2D383145Q47951404-401A52B4-58DD-469B-84F6-EE0656BBA0C8Q50099990-04A5E2B4-449E-4C13-AFD4-FDE8FFF194ECQ57287569-CD9976C8-965A-4F4E-A9A7-786656D8B517
P2860
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Elevated pretreatment serum le ...... arge B-cell lymphoma patients.
@ast
Elevated pretreatment serum le ...... arge B-cell lymphoma patients.
@en
type
label
Elevated pretreatment serum le ...... arge B-cell lymphoma patients.
@ast
Elevated pretreatment serum le ...... arge B-cell lymphoma patients.
@en
prefLabel
Elevated pretreatment serum le ...... arge B-cell lymphoma patients.
@ast
Elevated pretreatment serum le ...... arge B-cell lymphoma patients.
@en
P2093
P2860
P50
P356
P1476
Elevated pretreatment serum le ...... large B-cell lymphoma patients
@en
P2093
Ahmet Dogan
Anne J Novak
Stephen M Ansell
Steven C Ziesmer
Susan L Slager
Thomas E Witzig
Thomas M Habermann
William R Macon
P2860
P304
P356
10.1002/AJH.23259
P577
2012-06-03T00:00:00Z